Here we go again. Millions of dollars being spent to find yet another diabetes medication….and maybe, just maybe, this one won’t cause life threatening side effects. The drug being developed is in the same family as Rezulin, Avandia, and Actos all of which are classed as thiazolidinediones or TZD’s.
A little history of the 3 prior TZD’s:
Rezulin…withdrawn from the market in 2000 based on liver toxicity.
Avandia….2010..Banned in Europe and only available in the US through a restricted access program as it has been shown to cause fluid retention that can lead to congestive heart failure, increases risk of heart attacks, bone fractures, edema, weight gain, anemia, and liver effects.
Actos….2011..FDA warns of increased risk of bladder cancer and pulled from the shelves in some European countries.
And now…more work on the TZD’s..and the results (when used in mice) look promising. Terrific. The results when mice were studied with Rezulin, Avandia, and Actos were promising, too.
Quote: “The most effective of these candidates, labeled SR1664, was tested in cultured cells and insulin-resistant mice in the Spiegelman laboratory. It was found to have potent anti-diabetic properties but caused no fluid retention or weight gain.”
That’s promising…but what about liver toxicity, edema, increased chance of CHF, heart attack, decreased bone density, bladder cancer, anemia?
I sincerely wish that pharmaceutical companies would stop releasing half-researched medications and polluting our bodies with toxic chemicals whose side effects are often worse than the disease symptoms they are “band-aiding.”